- Conditions
- Allergic Asthma
- Interventions
- Omalizumab
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 1,758
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Kidney Transplant
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 8
- States / cities
- San Francisco, California • Denver, Colorado • Springfield, Massachusetts + 5 more
- Conditions
- Age Related Macular Degeneration (AMD)
- Interventions
- GT005
- Genetic
- Lead sponsor
- Gyroscope Therapeutics Limited
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 22
- States / cities
- Poway, California • Durango, Colorado • Gainesville, Florida + 18 more
- Conditions
- Leukemia
- Interventions
- cytarabine, daunorubicin, midostaurin, placebo, dexamethasone acetate
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 717 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 170
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 126 more
- Conditions
- Small-Cell Lung Cancer
- Interventions
- Everolimus
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 5
- States / cities
- Fayetteville, Arkansas • Aurora, Colorado • Boston, Massachusetts + 2 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Iptacopan, Matching Placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Fullerton, California • Sacramento, California + 10 more
- Conditions
- Solid Tumor, Hematologic Malignancies
- Interventions
- BGJ398
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Oceanside, California • San Francisco, California + 49 more
- Conditions
- Osteoporosis, Hip Fracture
- Interventions
- Zoledronic Acid
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 2,127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Eureka, California • La Mesa, California + 24 more
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Chordoma and Alveolar Soft Part Sarcoma
- Interventions
- FAZ053, PDR001
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Graft Rejection
- Interventions
- everolimus, mycophenolate mofetil, cyclosporine, corticosteroids
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 721 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 26
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 19 more
- Conditions
- Anemia, Sickle Cell
- Interventions
- ICL670, deferoxamine
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 34
- States / cities
- Mobile, Alabama • Loma Linda, California • Los Angeles, California + 25 more
- Conditions
- C3G
- Interventions
- Placebo, iptacopan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 13
- States / cities
- Aurora, Colorado • Miami, Florida • Lawrenceville, Georgia + 9 more
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Familial Mediterranean Fever
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Up to 28 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following, Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
- Interventions
- midostaurin, Bortezomib, mitoxantrone hydrochloride, etoposide, cytarabine
- Drug
- Lead sponsor
- Alison Walker
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 945 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Spinal Muscular Atrophy
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Up to 5 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Bannockburn, Illinois
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,882 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 74 more
- Conditions
- Systemic Sclerosis, Scleroderma
- Interventions
- STI571
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts
- Conditions
- Chronic Heart Failure
- Interventions
- RLX030 (serelaxin), Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 9
- States / cities
- Anaheim, California • Colorado Springs, Colorado • Jacksonville, Florida + 5 more
- Conditions
- Healthy
- Interventions
- sotrastaurin, placebo to sotrastaurin, Avelox
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Metastatic Melanoma
- Interventions
- RAF265
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Augusta, Georgia • Baltimore, Maryland + 5 more
- Conditions
- Polycythemia Vera (PV)
- Interventions
- Ruxolitinib
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1,576 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Heart Transplantation
- Interventions
- Enteric-coated Mycophenolate Sodium
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 162 participants
- Timeline
- Started 2002
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Minneapolis, Minnesota • Philadelphia, Pennsylvania